? Clinical, Epidemiology and Health Economics and Outcomes Research Shared at Key Psychiatry Conference ? DUBLIN, Sept. 20, 2022 /PRNewswire/ Alkermes plc (Nasdaq: ALKS) today announced
/PRNewswire/ Alkermes plc (Nasdaq: ALKS) today announced plans to present data from the ARTISTRY-1 clinical trial for nemvaleukin alfa (nemvaleukin), the.
- ARTISTRY-1 Data Showed Anti-Tumor Activity of Nemvaleukin, as a Monotherapy and in Combination with Pembrolizumab, in Multiple Tumor Types - - Company to Host Investor Webcast on June
/PRNewswire/ Alkermes plc (Nasdaq: ALKS) today presented new research from its psychiatry portfolio at the 2022 Congress of the Schizophrenia International.
- Detailed Results Presented From ENLIGHTEN-Early Phase 3b Study of LYBALVI in Patients Early in Illness - DUBLIN, April 7, 2022 /PRNewswire/ Alkermes plc (Nasdaq: ALKS) today presented